Clinical Trial Update: Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating iparomlimab and tuvonralimab with Bevacizumab and CAPEOX as conversion therapy for colorectal cancer with liver metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Cancer with Liver Metastases

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver | Phase 2 | Status: NOT_YET_RECRUITING